"A 2-treatment period, randomized, placebo-controlled,multicenter parallel-group study to assess the safety ofQAW039 when added to existing asthma therapy in GINAsteps 3, 4 and 5 patients with uncontrolled asthma"

drug protocol number
CQAW039A2315
drug sponsor
Novartis
drug study
QAW039/Fevipiprant
drug trial site
King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Jeddah)
drug status
Ongoing
drug phase